These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 18686225)

  • 1. Intensive glycemic control lowers plasma visfatin levels in patients with type 2 diabetes.
    Zhu J; Schott M; Liu R; Liu C; Shen B; Wang Q; Mao X; Xu K; Wu X; Schinner S; Papewalis C; Scherbaum WA; Liu C
    Horm Metab Res; 2008 Nov; 40(11):801-5. PubMed ID: 18686225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus.
    Erdem G; Dogru T; Tasci I; Bozoglu E; Muhsiroglu O; Tapan S; Ercin CN; Sonmez A
    Diabetes Res Clin Pract; 2008 Nov; 82(2):214-8. PubMed ID: 18778865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects.
    Li L; Yang G; Li Q; Tang Y; Yang M; Yang H; Li K
    Exp Clin Endocrinol Diabetes; 2006 Nov; 114(10):544-8. PubMed ID: 17177135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Association between both resistin, visfatin and insulin resistance as well as β cell function in the first-degree relatives of type 2 diabetes mellitus].
    Zhang XJ; Wang Z; Li HH; Yu L; Gao S
    Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Dec; 31(12):1393-6. PubMed ID: 21223671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma visfatin concentrations in subjects with type 1 diabetes mellitus.
    Toruner F; Altinova AE; Bukan N; Arslan E; Akbay E; Ersoy R; Arslan M
    Horm Res; 2009; 72(1):33-7. PubMed ID: 19571557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.
    Dogru T; Sonmez A; Tasci I; Bozoglu E; Yilmaz MI; Genc H; Erdem G; Gok M; Bingol N; Kilic S; Ozgurtas T; Bingol S
    Diabetes Res Clin Pract; 2007 Apr; 76(1):24-9. PubMed ID: 16956691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of visfatin in the pathogenesis of gestational diabetes mellitus and its relationship with insulin resistance].
    Huo Y; Liu S; Feng J; Li H; Fan Y; Jin Y; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2014 Aug; 49(8):584-7. PubMed ID: 25354858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
    Kadoglou NP; Tsanikidis H; Kapelouzou A; Vrabas I; Vitta I; Karayannacos PE; Liapis CD; Sailer N
    Metabolism; 2010 Mar; 59(3):373-9. PubMed ID: 19815243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compare the effects of different visfatin concentration on cardiovascular risk factors, adiponectin and insulin resistance in patients with T2DM.
    Mohammadi S; Hosseinzadeh-Attar MJ; Hosseinnezhad A; Hosseini SH; Eshraghian MR; Nezhad MK; Rahmani M; Karimi M
    Diabetes Metab Syndr; 2011; 5(2):71-5. PubMed ID: 22813406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The efficacy and safety of human glucagon-like peptide-1 analogue liraglutide in newly diagnosed type 2 diabetes with glycosylated hemoglobin A1c > 9].
    Yan L; Wang S; Chen P; Chen C; Shao Z; Xu X; Huang Q
    Zhonghua Nei Ke Za Zhi; 2015 Apr; 54(4):307-12. PubMed ID: 26268058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of visfatin in the prediction of metabolic syndrome: a multi-factorial analysis.
    Esteghamati A; Morteza A; Zandieh A; Jafari S; Rezaee M; Nakhjavani M; Jamali A; Esteghamati AR; Khalilzadeh O
    J Cardiovasc Transl Res; 2012 Aug; 5(4):541-6. PubMed ID: 22585407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes.
    Derosa G; D'Angelo A; Romano D; Maffioli P
    Drug Des Devel Ther; 2017; 11():1481-1488. PubMed ID: 28553078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visfatin and endogenous secretory receptor for advanced glycation end-products in diabetic type 2 and non-diabetic patients undergoing intermittent hemodialysis.
    Niepolski L; Grzegorzewska AE; Młot-Michalska M
    Int Urol Nephrol; 2010 Jun; 42(2):441-52. PubMed ID: 19184512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visfatin levels do not change after the oral glucose tolerance test and after a dexamethasone-induced increase in insulin resistance in humans.
    Marcinkowska M; Lewandowski KC; Lewiński A; Bieńkiewicz M; Basińska-Lewandowska M; Salata I; Randeva HS
    Endokrynol Pol; 2007; 58(3):188-94. PubMed ID: 17940983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of serum chemerin and inflammatory factors with type 2 diabetes macroangiopathy and waist-to-stature ratio.
    Yang M; Zhou X; Xu J; Yang B; Yu J; Gong Q; Zhang X; Sun X; Zhang Q; Xia J; Li J
    Bosn J Basic Med Sci; 2019 Nov; 19(4):328-335. PubMed ID: 31078135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visfatin genotype may modify the insulin resistance and lipid profile in type 2 diabetes patients.
    Mirzaei K; Hossein-Nezhad A; Javad Hosseinzadeh-Attar M; Jafari N; Najmafshar A; Mohammadzadeh N; Larijani B
    Minerva Endocrinol; 2009 Dec; 34(4):273-9. PubMed ID: 20046156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
    Miyazaki Y; Mahankali A; Matsuda M; Glass L; Mahankali S; Ferrannini E; Cusi K; Mandarino LJ; DeFronzo RA
    Diabetes Care; 2001 Apr; 24(4):710-9. PubMed ID: 11315836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating IRAPe, Irisin, and IL-34 in Relation to Insulin Resistance in Patients With Type 2 Diabetes.
    Mostafa TM; El-Gharbawy NM; Werida RH
    Clin Ther; 2021 Jul; 43(7):e230-e240. PubMed ID: 34103176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved glycemic control increases fasting plasma acylation-stimulating protein and decreases leptin concentrations in type II diabetic subjects.
    Ozata M; Gungor D; Turan M; Ozisik G; Bingol N; Ozgurtas T; Ozdemir IC
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3659-64. PubMed ID: 11502793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of non-surgical periodontal treatment on visfatin concentrations in serum and gingival crevicular fluid of patients with chronic periodontitis and type 2 diabetes mellitus.
    Wu Y; Chen L; Wei B; Luo K; Yan F
    J Periodontol; 2015 Jun; 86(6):795-800. PubMed ID: 25786566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.